ATRX
Use
Defects in ATRX are the cause of alpha-thalassemia/intellectual disability syndrome X-linked (ADRX). Acquired somatic hypermutations of the ATRX gene have been observed in chronic myeloid disorders. Loss of ATRX protein expression has been observed in neurologic tumors and pancreatic neuroendocrine tumors.
Special Instructions
Not provided.
Limitations
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected. Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Methodology
Immunoassay (IHC)
Biomarkers
ATRX
Protein
Result Turnaround Time
2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (Fresh)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Fixative should be at a 20:1 fixative to tissue ratio, 10% neutral buffered formalin (NBF) for 6-72 hours (48-72 hours PREFERRED).
Storage Instructions
Specimens may be transferred to 70% alcohol for transportation purposes after fixation.
Causes for Rejection
Specimens must be fixed in 10% NBF or B plus. All other fixatives will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | ≤ 72 Hours |